SG10201913419TA - Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same - Google Patents
Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the sameInfo
- Publication number
- SG10201913419TA SG10201913419TA SG10201913419TA SG10201913419TA SG10201913419TA SG 10201913419T A SG10201913419T A SG 10201913419TA SG 10201913419T A SG10201913419T A SG 10201913419TA SG 10201913419T A SG10201913419T A SG 10201913419TA SG 10201913419T A SG10201913419T A SG 10201913419TA
- Authority
- SG
- Singapore
- Prior art keywords
- treating
- same
- cognitive disorders
- preventing cognitive
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017035594A JP2018139530A (en) | 2017-02-27 | 2017-02-27 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913419TA true SG10201913419TA (en) | 2020-03-30 |
Family
ID=62025891
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913419TA SG10201913419TA (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
SG11201907548PA SG11201907548PA (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907548PA SG11201907548PA (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
Country Status (26)
Country | Link |
---|---|
US (3) | US10556950B2 (en) |
EP (1) | EP3585810A1 (en) |
JP (3) | JP2018139530A (en) |
KR (1) | KR20190122674A (en) |
CN (2) | CN110382528A (en) |
AR (2) | AR110875A1 (en) |
AU (1) | AU2018224390A1 (en) |
BR (1) | BR112019016490A2 (en) |
CA (1) | CA3052538A1 (en) |
CL (2) | CL2019002296A1 (en) |
CO (1) | CO2019008786A2 (en) |
CR (1) | CR20190363A (en) |
DO (1) | DOP2019000215A (en) |
EA (1) | EA201991726A1 (en) |
GE (1) | GEP20227392B (en) |
IL (1) | IL267945A (en) |
JO (1) | JOP20180014A1 (en) |
MA (1) | MA47608A (en) |
MX (1) | MX2019009945A (en) |
MY (1) | MY193821A (en) |
NI (1) | NI201900086A (en) |
PE (1) | PE20191614A1 (en) |
PH (1) | PH12019501929A1 (en) |
SG (2) | SG10201913419TA (en) |
TW (1) | TW201843179A (en) |
WO (2) | WO2018154392A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110520440A (en) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | Anti- τ antibody and its application method |
JOP20180014A1 (en) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
TW202340244A (en) | 2017-10-16 | 2023-10-16 | 日商衛材R&D企管股份有限公司 | Anti-tau antibodies and uses thereof |
AU2020325770B2 (en) * | 2019-08-06 | 2022-08-25 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
EP4159860A1 (en) * | 2020-06-02 | 2023-04-05 | Teijin Pharma Limited | Anti-igf-1 receptor humanized antibody |
AU2021297873A1 (en) | 2020-06-25 | 2023-02-09 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS587390B2 (en) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | arc |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
JP3587390B2 (en) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | Phosphorylated amino acid derivative and phosphorylated peptide synthesis method |
US7754497B2 (en) | 2003-08-29 | 2010-07-13 | Reverse Proteomics Research Institute Co., Ltd. | Method for immobilizing proteins |
EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | Methods of generating variant proteins with increased host string content and compositions thereof |
UA107571C2 (en) | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
CN103502272B (en) * | 2010-10-07 | 2016-06-15 | Ac免疫有限公司 | Identify the phosphorylation specific antibody of Tau |
SI2627672T1 (en) * | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
MY186066A (en) | 2011-12-20 | 2021-06-18 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
US20150183854A1 (en) | 2012-05-31 | 2015-07-02 | Teijin Pharma Limited | Therapeutic agent or prophylactic agent for dementia |
BR112015003326A2 (en) * | 2012-08-16 | 2017-07-04 | Ipierian Inc | methods of treatment of a tauopathy |
PT2935326T (en) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Human anti-tau antibodies |
ES2800827T3 (en) | 2013-06-10 | 2021-01-04 | Ipierian Inc | Treatment procedures for a tauopathy |
SI3083680T1 (en) | 2013-12-20 | 2020-06-30 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
AR100978A1 (en) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
TWI734975B (en) * | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | Humanized anti-tau antibodies |
US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
WO2016112078A2 (en) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
CN107849105B (en) | 2015-07-06 | 2021-09-17 | Ucb生物制药有限责任公司 | TAU binding antibodies |
NZ738058A (en) | 2015-07-06 | 2021-07-30 | UCB Biopharma SRL | Tau-binding antibodies |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
JOP20180014A1 (en) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
-
2017
- 2017-02-27 JO JOP/2018/0014A patent/JOP20180014A1/en unknown
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/en active Pending
-
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/en active Application Filing
- 2018-02-26 TW TW107106444A patent/TW201843179A/en unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/en active Pending
- 2018-02-27 EP EP18718907.1A patent/EP3585810A1/en active Pending
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/en active Application Filing
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/en active Active
- 2018-02-27 MA MA047608A patent/MA47608A/en unknown
- 2018-02-27 AU AU2018224390A patent/AU2018224390A1/en active Pending
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 KR KR1020197024146A patent/KR20190122674A/en not_active Application Discontinuation
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/en unknown
- 2018-02-27 CR CR20190363A patent/CR20190363A/en unknown
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/en active Pending
- 2018-02-27 AR ARP180100454A patent/AR110875A1/en unknown
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/en unknown
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/en active Active
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/en unknown
- 2018-02-27 EA EA201991726A patent/EA201991726A1/en unknown
-
2019
- 2019-07-09 IL IL267945A patent/IL267945A/en unknown
- 2019-08-09 NI NI201900086A patent/NI201900086A/en unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/en unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/en unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/en unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/en unknown
-
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
-
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/en unknown
-
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267945A (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
EP3661676C0 (en) | Feedstocks for additive manufacturing, and methods of using the same | |
EP3615521A4 (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
IL266596A (en) | Agents, uses and methods for the treatment of synucleinopathy | |
MX2017004715A (en) | Humanized anti-ox40 antibodies and uses thereof. | |
SG11201802506QA (en) | Denitration catalyst and method for producing the same | |
PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
IL273705A (en) | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | |
IL269645A (en) | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof | |
IL262747A (en) | Anti-kv1.3 antibodies, and methods of production and use thereof | |
IL268007A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis | |
IL271728A (en) | Agents, uses and methods for treatment | |
PT3458467T (en) | Process and intermediates for the 6,7-alpha-epoxidation of steroid 4,6-dienes | |
IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
ZA202203776B (en) | Methods of treating epilepsy using the same | |
IL276358A (en) | Compounds and methods for treating addiction and related disorders | |
PL3394019T3 (en) | Method for producing and purifying 2,3,3,3-tetrafluoropropene | |
GB201615209D0 (en) | Catalyst and process using the catalyst | |
GB201615197D0 (en) | Catalyst and process using the catalyst | |
SG10202009001TA (en) | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | |
SG10202007257QA (en) | Hydrogenation treatment catalyst for hydrocarbon oil, method for producing the same, and hydrogenation treatment method | |
EP3678651A4 (en) | Methods for treating urea cycle disorders | |
EP3550466C0 (en) | Puf-film and method for producing the same | |
EP3481432A4 (en) | Diagnosing col6-related disorders and methods for treating same | |
PL3360981T3 (en) | Steel component manufactured by hot forming, method of manufacturing and use of the component |